A team of researchers at Florida International University (FIU) has uncovered a potential early indicator of Alzheimer’s disease linked to a brain protein. This breakthrough could pave the way for identifying neurodegeneration years before symptoms typically manifest. The study focused on the translocator protein 18 kDa, or TSPO, previously associated with inflammation in Alzheimer’s patients.
In experiments using mouse models, researchers found that elevated levels of TSPO appeared as early as six weeks, which corresponds to approximately 18 to 20 human years. These increased levels were particularly noted in the subiculum, an area of the brain vital for memory formation. This discovery raises the possibility of using TSPO as a biomarker for early detection of Alzheimer’s.
Understanding the Implications of TSPO
The research team also examined brain tissue from nine individuals in Colombia who carried a genetic mutation leading to early-onset Alzheimer’s, typically developing symptoms in their 30s or 40s. They observed similar patterns of TSPO elevation, reinforcing the connection between this protein and Alzheimer’s pathology.
Tomás Guilarte, a neuroscientist at FIU, emphasized the significance of neuroinflammation as an early event influencing the disease’s onset. He stated, “If we can use TSPO to detect it early, right at the beginning stages of the disease, it could mean slowing progression or delaying symptoms by five or six years. That’s five or six years where someone has a better quality of life.”
The study revealed that female mice exhibited higher levels of TSPO, reflecting existing data that suggests women are more susceptible to developing Alzheimer’s. Additionally, the rise in TSPO levels coincided with the emergence of amyloid-beta plaques, which are protein clumps associated with the disease. Notably, the increase in TSPO was primarily found in immune cells known as microglia, which had responded to the plaque accumulation.
Future Directions for Research
The findings provide crucial insights into the origins of Alzheimer’s, presenting clues about the chemical reactions that might help slow or halt its progression. Guilarte pointed out that microglia appear to play a central role in the inflammatory response: “What we believe is happening is something goes wrong with the microglia. They stop doing their job in removing the plaques and just keep sending out TSPO signals. This constant signal of neuroinflammation is like adding wood to a fire.”
While the study primarily focused on genetic cases of Alzheimer’s, which are relatively rare, the researchers plan to expand their investigation to better understand the role of TSPO in broader populations. The challenge remains to differentiate causes from consequences in Alzheimer’s pathology, but this brain biomarker may serve as a vital early warning system.
Neuroscientist Daniel Martinez-Perez expressed hope that this research could lead to earlier interventions. “One of the biggest problems with Alzheimer’s is people see it as a disease of aging, and that impacts when people get diagnosed. My hope is we can be part of helping people before they are too sick.”
The study findings have been published in the journal Acta Neuropathologica, contributing to the growing body of knowledge surrounding Alzheimer’s disease and its early detection.
